Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avidity Biosciences, Inc.

25.58
+1.476.10%
Post-market: 25.580.00000.00%17:29 EDT
Volume:1.55M
Turnover:39.15M
Market Cap:3.08B
PE:-8.86
High:25.80
Open:24.04
Low:23.66
Close:24.11
Loading ...

Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025

GlobeNewswire
·
25 Feb

Arrowhead presents preclinical results on ARO-ALK7

TIPRANKS
·
25 Feb

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

Business Wire
·
25 Feb

Maravai Lifesciences Completes Acquisition of Officinae Bio's DNA and RNA Business

MT Newswires Live
·
24 Feb

Maravai LifeSciences Completes Acquisition of the DNA and RNA Business of Officinae Bio

Business Wire
·
24 Feb

PYC Therapeutics Launches Retail Entitlement Offer to Fund RNA Therapy Development

TIPRANKS
·
24 Feb

BRIEF-Avidity Biosciences Announces Inducement Grants

Reuters
·
22 Feb

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
22 Feb

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
22 Feb

Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025

GlobeNewswire
·
20 Feb

Avidity Biosciences: Undervalued Entry Point with Promising 2025 Pipeline Despite Market Challenges

TIPRANKS
·
17 Feb

We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely

Simply Wall St.
·
29 Jan

Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies

GlobeNewswire
·
22 Jan

Avidity Biosciences Price Target Maintained With a $67.00/Share by RBC Capital

Dow Jones
·
22 Jan

U.S. RESEARCH ROUNDUP- Apple, Murphy USA, UnitedHealth

Reuters
·
21 Jan

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
21 Jan

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
21 Jan

Bank of America Securities Remains a Buy on Avidity Biosciences (RNA)

TIPRANKS
·
15 Jan

Avidity Biosciences: Strategic Advancements in Key Programs Drive Buy Rating

TIPRANKS
·
15 Jan

Wave Life Sciences: Buy Rating Based on Promising Clinical Updates and RNA Editing Advancements

TIPRANKS
·
14 Jan